Preview

Онкоурология

Расширенный поиск

Применение гозерелина ацетата в сочетании с лучевой терапией при лечении рака предстательной железы

https://doi.org/10.17650/1726-9776-2008-4-2-69-72

Полный текст:

Об авторе

Mask Roach III & Alejandra Izaguirre
Department of Radiation Oncology, University of California San Francisco, UCSF Comprehensive Cancer Center
Соединённые Штаты Америки
1600 Divisadero Street, Suite H1031, San Francisco, California 94143-1708, USA Expert Opin Pharmacother 2007;8(2):257–64


Список литературы

1. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.

2. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–80.

3. Johansson J.E., Andren O., Andersson S.O. et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713–9.

4. Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243–52.

5. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 2002;360:103–6.

6. Roach M. III, Desilvio M., Lawton C. et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. Clin Oncol 2003;21:1904–11.

7. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. Clin Oncol 2003;21:3972–8.

8. Laverdiere J., Gomez J.L., Cusan L. et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247–52.

9. D'Amico A.V., Manola J., Loffredo M. et al. 6-Month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821–7.

10. Crook J., Ludgate C., Malone S. et al. Report of a multicenter Canadian Phase III randomized trial of 3 months versus 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:15–23.

11. Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–90.

12. Denham J.W., Steigler A., Lamb D.S. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–50.

13. Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Clin Oncol 1997;15:1013–21.

14. Granfors T., Modig H., Damber J.E., Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. Urology 1998;159:2030–4.

15. Roach M., Lu J., Pilepich M.V. et al. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617–27.

16. Laverdiere J., Nabid A., De Bedoya L.D. et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. Urology 2004;171:1137–40.

17. Physicians' Desk Reference, 60th edn. Thomson P.D.R., Montvale N.J.; 2006:709–l4.


Для цитирования:


Roach III & Alejandra Izaguirre M. Применение гозерелина ацетата в сочетании с лучевой терапией при лечении рака предстательной железы. Онкоурология. 2008;4(2):69-72. https://doi.org/10.17650/1726-9776-2008-4-2-69-72

For citation:


Roach III & Alejandra Izaguirre M. The Use of Goserelin acetate in combination with radiotherapy for prostate cancer. Cancer Urology. 2008;4(2):69-72. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-2-69-72

Просмотров: 35


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X